Published in Curr Pharm Des on January 01, 2007
VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol (2012) 0.99
A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett (2012) 0.89
Vasoactive intestinal peptide signaling axis in human leukemia. World J Biol Chem (2011) 0.79
VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man. Urology (2015) 0.79
Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy. PLoS One (2011) 0.77
Epigenetic control of cancer by neuropeptides. Biomed Rep (2016) 0.75
VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235. Endocr Connect (2014) 0.75
Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Curr Opin Endocrinol Diabetes Obes (2016) 0.75
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol (2012) 1.64
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2008) 1.41
Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res (2003) 1.38
Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther (2007) 1.30
NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis (2009) 1.26
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24
Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol (2006) 1.14
A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem (2004) 1.12
Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem (2007) 1.12
Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem (2006) 1.08
PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci (2005) 1.06
PolyADP-ribosylation is required for long-term memory formation in mammals. J Neurochem (2009) 1.03
NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke (2002) 1.01
Neuroprotective protein and carboxypeptidase E. J Mol Neurosci (2009) 0.99
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci (2010) 0.98
ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci (2008) 0.98
Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Res Rev (2006) 0.97
Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther (2004) 0.97
Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol (2004) 0.96
Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci (2005) 0.95
Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol (2010) 0.95
NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis (2013) 0.94
Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis (2011) 0.93
NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr Pharm Des (2007) 0.92
Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett (2004) 0.92
NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Ann N Y Acad Sci (2006) 0.91
The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One (2012) 0.90
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat (2012) 0.90
Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. J Biol Chem (2012) 0.90
Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci (2007) 0.89
The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci (2005) 0.88
NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur J Pharmacol (2009) 0.87
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides (2010) 0.87
Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci (2009) 0.86
Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept (2004) 0.86
Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis (2012) 0.86
The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides (2003) 0.86
Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des (2011) 0.86
NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther (2006) 0.85
Complex array of cytokines released by vasoactive intestinal peptide. Neuropeptides (2003) 0.84
Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem (2007) 0.84
A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. Life Sci (2002) 0.84
(N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J Mol Neurosci (2002) 0.83
NAP protects hippocampal neurons against multiple toxins. Peptides (2007) 0.83
The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem (2009) 0.82
The pregnant spontaneously hypertensive rat as a model of asymmetric intrauterine growth retardation and neurodevelopmental delay. Hypertens Pregnancy (2005) 0.82
The effects of vascular intrauterine growth retardation on cortical astrocytes. J Matern Fetal Neonatal Med (2010) 0.81
Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. J Pept Sci (2008) 0.81
Antagonism of VIP-stimulated cyclic AMP formation in chick brain. J Mol Neurosci (2003) 0.81
VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides (2006) 0.81
Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides (2013) 0.81
Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci (2006) 0.81
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy (2014) 0.81
Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides (2005) 0.80
Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opin Investig Drugs (2007) 0.80
NAP protects against cyanide-related microtubule destruction. J Neural Transm (Vienna) (2009) 0.80
Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. J Mol Neurosci (2007) 0.79
A novel method for analyzing mitochondrial movement: inhibition by paclitaxel in a pheochromocytoma cell model. J Mol Neurosci (2008) 0.79
D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. J Mol Neurosci (2012) 0.79
Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett (2005) 0.79
3R tau expression modifies behavior in transgenic mice. J Neurosci Res (2010) 0.78
A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis. J Mol Neurosci (2002) 0.78
Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. Neuroreport (2003) 0.78
VIP and PACAP: novel approaches to brain functions and neuroprotection. Curr Pharm Des (2011) 0.77
In vitro and in vivo treatment of colon cancer by VIP antagonists. Regul Pept (2002) 0.76
The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP. Biol Chem (2016) 0.76
Brain injury-dependent expression of activity-dependent neuroprotective protein. J Mol Neurosci (2004) 0.76
Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol. J Neural Transm (Vienna) (2008) 0.76
Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development. Am J Obstet Gynecol (2002) 0.76
Apolipoprotein E knockout mice as a model of behavioral dysfunction. J Mol Neurosci (2004) 0.76
Novel extended and branched N-terminal analogs of VIP. Regul Pept (2006) 0.75
The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides (2005) 0.75
Novel analogs of VIP with multiple C-terminal domains. Peptides (2007) 0.75
Inge Grundke-Iqbal, Ph.D. (1937–2012): the discoverer of the abnormal hyperphosphorylation of tau in Alzheimer’s disease. J Mol Neurosci (2013) 0.75
The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase. Regul Pept (2002) 0.75
A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes. Ann N Y Acad Sci (2006) 0.75
In memory of our teacher, Dr. Akira Arimura. J Mol Neurosci (2008) 0.75
Summer neuropeptide conference. The 3rd joint meeting of the summer neuropeptide conference (13th annual meeting) and the European Neuropeptide Club (13th annual meeting) Montauk, NY, June 8-12, 2003. Neuropeptides (2003) 0.75
8th international symposium on VIP, PACAP related peptides. Introduction. J Mol Neurosci (2008) 0.75
Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding. J Mol Neurosci (2005) 0.75
Ameliorative effect of NAP on laser-induced retinal damage. Acta Ophthalmol (2011) 0.75
Protein synthesis in nuclei: when did the story start? J Mol Neurosci (2002) 0.75
Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection. J Mol Neurosci (2004) 0.75
The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley. Expert Opin Ther Targets (2007) 0.75